AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15085500 — intervention group
Group type: EXPERIMENTAL
Intervention: Right lateral decubitus
Number of subjects: 31
Study 15085500 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 31
Study 15085500 — intervention group
Group type: COMPARATOR
Intervention: Left lateral decubitus
Number of subjects: 31
Study 15085500 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 31
Study 11739159 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin + ara-C (IA)
Number of subjects: 1279
Study 11739159 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine + ara-C (FA)
Number of subjects: 1279
Study 11739159 — intervention group
Group type: COMPARATOR
Intervention: Topotecan + ara-C (TA)
Number of subjects: 1279
Study 9161812 — intervention group
Group type: EXPERIMENTAL
Intervention: Occult blood screening test (haemoccult IIR) offered by GPs, occupational health doctors, and pharmacists from February 1993 to June 1994.
Number of subjects: 585
Study 9161812 — intervention group
Group type: COMPARATOR
Intervention: Intention to take the screening test.
Number of subjects: 585
Study 9161812 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociodemographic and cultural characteristics influencing participation.
Number of subjects: 585
Study 8107615 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg oral oestriol/day for 3 months
Number of subjects: 64
Study 8107615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 3312371 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care with 1.5 million units streptokinase intravenously
Number of subjects: 11712
Study 3312371 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 11712
Study 29902470 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Mechanical Peripheral Stimulation (AMPS)
Number of subjects: 30
Study 29902470 — intervention group
Group type: COMPARATOR
Intervention: AMPS sham
Number of subjects: 30
Study 28651442 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 695502 (1 mg/kg)
Number of subjects: 91
Study 28651442 — intervention group
Group type: COMPARATOR
Intervention: US-approved Avastin (1 mg/kg)
Number of subjects: 91
Study 28651442 — intervention group
Group type: COMPARATOR
Intervention: EU-approved Avastin (1 mg/kg)
Number of subjects: 91
Study 26813432 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronochemotherapy
Number of subjects: 70
Study 26813432 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 70
Study 23797426 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of ASA
Number of subjects: 254
Study 23797426 — intervention group
Group type: COMPARATOR
Intervention: 75 mg of clopidogrel
Number of subjects: 254
Study 21102260 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m and carboplatin AUC 6 once every 3 weeks for up to 6 cycles with enzastaurin 1125 or 1200 mg loading dose followed by 500 mg daily until disease progression
Number of subjects: 218
Study 21102260 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m and carboplatin AUC 6 once every 3 weeks for up to 6 cycles without enzastaurin
Number of subjects: 218
Study 21102260 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m and carboplatin AUC 6 once every 3 weeks for up to 6 cycles
Number of subjects: 218
Study 18511306 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant treatment (psychomotor stimulant)
Number of subjects: 20
Study 18511306 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal treatment (ADHD group assessed once on normal treatment)
Number of subjects: 20
Study 18511306 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal from treatment (ADHD group assessed after withdrawing from treatment for at least one week)
Number of subjects: 20
Study 18511306 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched control subjects)
Number of subjects: 20
Study 16328487 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (no DR)
Number of subjects: 40
Study 16328487 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (mild/moderate DR)
Number of subjects: 40
Study 16328487 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III (moderate/severe nonproliferative DR with laser treatment)
Number of subjects: 40
Study 16328487 — intervention group
Group type: EXPERIMENTAL
Intervention: Group IV (proliferative DR with laser treatment)
Number of subjects: 40
Study 14996265 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anaesthesia with ketamine and propofol (group P)
Number of subjects: 135
Study 14996265 — intervention group
Group type: COMPARATOR
Intervention: Inhalation anaesthesia with sevoflurane by LMA (group S)
Number of subjects: 135
Study 10890330 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761 (180 mg/d)
Number of subjects: 40
Study 10890330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9131955 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg twice daily)
Number of subjects: 12
Study 9131955 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 12
Study 9131955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8383769 — intervention group
Group type: EXPERIMENTAL
Intervention: Guava fruit intake (0.5-1.0 kg daily)
Number of subjects: 145
Study 8383769 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (control group)
Number of subjects: 145
Study 3526853 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.55 mg/kg cibenzoline
Number of subjects: 25
Study 3526853 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.80 mg/kg cibenzoline
Number of subjects: 25
Study 3526853 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.2 mg/kg cibenzoline
Number of subjects: 25
Study 3526853 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.6 mg/kg cibenzoline
Number of subjects: 25
Study 29076234 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support
Number of subjects: 134
Study 29076234 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 134
Study 28470118 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet rich in industrial trans fatty acids
Number of subjects: 9
Study 28470118 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet rich in trans fatty acids from ruminants
Number of subjects: 9
Study 28470118 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet low in trans fatty acids
Number of subjects: 9
Study 25742207 — intervention group
Group type: EXPERIMENTAL
Intervention: MDDScore (biomarker panel including 9 biomarkers)
Number of subjects: 68
Study 25742207 — intervention group
Group type: EXPERIMENTAL
Intervention: MDDScore (biomarker panel including 9 biomarkers with gender and BMI effects)
Number of subjects: 68
Study 25742207 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall accuracy of MDDScore
Number of subjects: 68
Study 25742207 — intervention group
Group type: COMPARATOR
Intervention: Control group (nondepressed subjects), n = 86
Number of subjects: 68
Study 23244401 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher achieving children in 8th grade
Number of subjects: 0
Study 23244401 — intervention group
Group type: EXPERIMENTAL
Intervention: Low achieving children
Number of subjects: 0
Study 23244401 — intervention group
Group type: COMPARATOR
Intervention: Higher achieving children
Number of subjects: 0
Study 23244401 — intervention group
Group type: EXPERIMENTAL
Intervention: Fraction magnitude knowledge and whole number division
Number of subjects: 0
Study 21496312 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole brain radiotherapy (WBRT) at least 30 Gy in 10 fractions commenced within 8 weeks of surgery and/or SRS
Number of subjects: 43
Study 21496312 — intervention group
Group type: COMPARATOR
Intervention: Observation following local treatment of intracranial melanoma metastases with surgery and/or SRS
Number of subjects: 43
Study 18172629 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging (DTI)
Number of subjects: 18
Study 18172629 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up DTI study
Number of subjects: 18
Study 17117175 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta
Number of subjects: 1413
Study 15326260 — intervention group
Group type: EXPERIMENTAL
Intervention: safinamide (SAF) 70 mg/day (range 40 to 90 mg/day)
Number of subjects: 101
Study 15326260 — intervention group
Group type: EXPERIMENTAL
Intervention: safinamide (SAF)
Number of subjects: 101
Study 15326260 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 101
Study 11531679 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaraminol 0.5 mg
Number of subjects: 30
Study 11531679 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 30
Study 9439354 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-tension glaucoma with progressive visual field defects
Number of subjects: 59
Study 9439354 — intervention group
Group type: COMPARATOR
Intervention: Normal-tension glaucoma with stable visual field defects
Number of subjects: 59
Study 9439354 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucomatous patients with increased intraocular pressure and progressive visual field defects
Number of subjects: 59
Study 9439354 — intervention group
Group type: COMPARATOR
Intervention: Glaucomatous patients with increased intraocular pressure and stable visual field defects
Number of subjects: 59
Study 8315260 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-interferon (10 MU/m2, three times weekly for 4 months)
Number of subjects: 32
Study 8315260 — intervention group
Group type: COMPARATOR
Intervention: Alpha- and gamma-interferon (2 MU/m2 of gamma-interferon and 10 MU/m2 of alpha-interferon)
Number of subjects: 32
Study 2894218 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg temazepam
Number of subjects: 12
Study 2894218 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg temazepam
Number of subjects: 12
Study 2894218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30794297 — intervention group
Group type: COMPARATOR
Intervention: Asian physicians
Number of subjects: 149775
Study 30794297 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Hispanic white physicians
Number of subjects: 149775
Study 30794297 — intervention group
Group type: COMPARATOR
Intervention: Asian patients
Number of subjects: 149775
Study 30794297 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Hispanic white patients
Number of subjects: 149775
Study 28827725 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutation rate estimation
Number of subjects: 3222
Study 28827725 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐crossover gene conversion rate estimation
Number of subjects: 3222
Study 28827725 — intervention group
Group type: EXPERIMENTAL
Intervention: C to T mutations in a 5' CCG 3' to 5' CTG 3' context
Number of subjects: 3222
Study 26342427 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferroquine 2 mg/kg plus artesunate
Number of subjects: 326
Study 26342427 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferroquine 4 mg/kg plus artesunate
Number of subjects: 326
Study 26342427 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferroquine 6 mg/kg plus artesunate
Number of subjects: 326
Study 26342427 — intervention group
Group type: COMPARATOR
Intervention: Ferroquine 4 mg/kg monotherapy
Number of subjects: 326
Study 23746559 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice (PJ)
Number of subjects: 27
Study 23746559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 21454017 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive users (third generation)
Number of subjects: 43
Study 21454017 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive users (new generation)
Number of subjects: 43
Study 21454017 — intervention group
Group type: COMPARATOR
Intervention: Non-users
Number of subjects: 43
Study 21454017 — intervention group
Group type: EXPERIMENTAL
Intervention: All OC users
Number of subjects: 43
Study 21454017 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (OC users and non-users)
Number of subjects: 43
Study 19738118 — intervention group
Group type: EXPERIMENTAL
Intervention: OBL-FC (oblimersen plus fludarabine/cyclophosphamide)
Number of subjects: 241
Study 19738118 — intervention group
Group type: COMPARATOR
Intervention: FC (fludarabine/cyclophosphamide)
Number of subjects: 241
Study 16414297 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled albuterol
Number of subjects: 4
Study 16414297 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled glucocorticoid/beta(2)-adrenergic agonist combination drug
Number of subjects: 4
Study 16414297 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment) for ex-smokers with COPD
Number of subjects: 4
Study 15109558 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional tea preparations of Artemisia annua
Number of subjects: 100
Study 15109558 — intervention group
Group type: COMPARATOR
Intervention: Quinine (control)
Number of subjects: 100
Study 11455223 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg dexamethasone premedication
Number of subjects: 132
Study 11455223 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg dexamethasone premedication
Number of subjects: 132
Study 11455223 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dexamethasone premedication
Number of subjects: 132
Study 9734750 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole treatment combined with phylloquinone-restricted diet
Number of subjects: 13
Study 9734750 — intervention group
Group type: COMPARATOR
Intervention: Phylloquinone-restricted diet alone
Number of subjects: 13
Study 9734750 — intervention group
Group type: EXPERIMENTAL
Intervention: Phylloquinone-restricted diet with omeprazole treatment
Number of subjects: 13
Study 9734750 — intervention group
Group type: COMPARATOR
Intervention: Phylloquinone-restricted diet
Number of subjects: 13
Study 8041982 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 31
Study 8041982 — intervention group
Group type: COMPARATOR
Intervention: Thiopental-Isoflurane
Number of subjects: 31
Study 2738549 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape patient education
Number of subjects: 22
Study 2738549 — intervention group
Group type: COMPARATOR
Intervention: Personalized teaching
Number of subjects: 22
Study 4555981 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-tetrahydrocannabinol administered by smoking
Number of subjects: 12
Study 4555981 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-tetrahydrocannabinol labeled with carbon-14
Number of subjects: 12
Study 4555981 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective symptoms
Number of subjects: 12
Study 30842392 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive lumbar stabilization exercises with respiratory resistance
Number of subjects: 43
Study 30842392 — intervention group
Group type: COMPARATOR
Intervention: Progressive lumbar stabilization exercises
Number of subjects: 43
Study 27739325 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib with temozolomide
Number of subjects: 0
Study 27739325 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib with carboplatin/paclitaxel
Number of subjects: 0
Study 27739325 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin/paclitaxel with placebo
Number of subjects: 0
Study 25783381 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative nasogastric tube (NGT)
Number of subjects: 50
Study 25783381 — intervention group
Group type: COMPARATOR
Intervention: No nasogastric tube (no NGT)
Number of subjects: 50
Study 23490598 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-fat diet counseling
Number of subjects: 1781
Study 22379876 — intervention group
Group type: COMPARATOR
Intervention: Standard intensive therapy of diabetic ketoacidosis
Number of subjects: 128
Study 22379876 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy for neuroprotection by actovegin
Number of subjects: 128
Study 22379876 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamberin on the background of standard therapy
Number of subjects: 128
Study 22379876 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of actovegin and reamberin
Number of subjects: 128
Study 19268494 — intervention group
Group type: EXPERIMENTAL
Intervention: gap200 condition (fixation spot removed, dimmed, expanded, or brightened 200ms before target onset)
Number of subjects: 0
Study 19268494 — intervention group
Group type: COMPARATOR
Intervention: gap0 condition (fixation offsets at target onset)
Number of subjects: 0
Study 19268494 — intervention group
Group type: COMPARATOR
Intervention: overlap condition (fixation spot stays on)
Number of subjects: 0
Study 16814082 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose coenzyme Q(10) (10.0 mg/kg/day)
Number of subjects: 16
Study 16814082 — intervention group
Group type: COMPARATOR
Intervention: Low-dose coenzyme Q(10) (1.0 mg/kg/day)
Number of subjects: 16
Study 12766622 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine 7.5 mg
Number of subjects: 27
Study 12766622 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine 15 mg
Number of subjects: 27
Study 12766622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 12766622 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg)
Number of subjects: 27
Study 12766622 — intervention group
Group type: COMPARATOR
Intervention: Placebo (beverage)
Number of subjects: 27
Study 11967790 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blockers (ARBs)
Number of subjects: 0
Study 11967790 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitors
Number of subjects: 0
Study 9327714 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment (HBO) combined with recombinant tissue plasminogen activator (rTPA)
Number of subjects: 66
Study 9327714 — intervention group
Group type: COMPARATOR
Intervention: rTPA alone (Control)
Number of subjects: 66
Study 8447041 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 306
Study 8447041 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 306
Study 3914572 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CSA)
Number of subjects: 96
Study 3914572 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 96
Study 3914572 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CSA) to Azathioprine (AZA) and prednisone
Number of subjects: 96
Study 30940692 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2292767A single dose (0.05-2 mg)
Number of subjects: 49
Study 30940692 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2292767A repeat dose (2 mg for 14 days)
Number of subjects: 49
Study 30940692 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2292767A
Number of subjects: 49
Study 30144891 — intervention group
Group type: EXPERIMENTAL
Intervention: TB patients
Number of subjects: 1605
Study 30144891 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected TB patients
Number of subjects: 1605
Study 30144891 — intervention group
Group type: EXPERIMENTAL
Intervention: TB treatment
Number of subjects: 1605
Study 30144891 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 1605
Study 30144891 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex and age
Number of subjects: 1605
Study 30144891 — intervention group
Group type: COMPARATOR
Intervention: Non-TB controls
Number of subjects: 1605
Study 27074126 — intervention group
Group type: EXPERIMENTAL
Intervention: Inositol at 80 mg/kg/d
Number of subjects: 122
Study 27074126 — intervention group
Group type: EXPERIMENTAL
Intervention: Inositol at 40 mg/kg/d
Number of subjects: 122
Study 27074126 — intervention group
Group type: EXPERIMENTAL
Intervention: Inositol at 10 mg/kg/d
Number of subjects: 122
Study 27074126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 24703523 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital plus home exercise programme
Number of subjects: 131
Study 24703523 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 131
Study 21364152 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 478
Study 21364152 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 478
Study 16145740 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg adjuvant to radiotherapy
Number of subjects: 1370
Study 16145740 — intervention group
Group type: COMPARATOR
Intervention: Placebo adjuvant to radiotherapy
Number of subjects: 1370
Study 12514911 — intervention group
Group type: EXPERIMENTAL
Intervention: Uroflowmetry
Number of subjects: 54
Study 9848529 — intervention group
Group type: EXPERIMENTAL
Intervention: Connective tissue graft including periosteum used as a barrier for guided periodontal tissue regeneration
Number of subjects: 22
Study 9848529 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement (control)
Number of subjects: 22
Study 7857734 — intervention group
Group type: EXPERIMENTAL
Intervention: Alacepril (37.5 mg)
Number of subjects: 12
Study 7857734 — intervention group
Group type: COMPARATOR
Intervention: Control group (11 patients)
Number of subjects: 12
Study 2479052 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycosaminoglycan polysulfate (Ateroid)
Number of subjects: 39
Study 1037254 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hydrazino-6-[N,N-bis-(2-hydroxyethyl)-amino]-pyridazine-dihydrochloride (DL 150 IT) at 50 mug/kg
Number of subjects: 5
Study 1037254 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine at 250 mug/kg
Number of subjects: 5
Study 28983557 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX chemotherapy
Number of subjects: 2636
Study 27662016 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus/sirolimus
Number of subjects: 209
Study 27662016 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine/methotrexate
Number of subjects: 209
Study 24744152 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-interval lower-dose (SILD) intravenous cyclophosphamide (CYC) - 12 fortnightly pulses at 400 mg followed by 6 monthly pulses
Number of subjects: 225